IP Library Granted Patent US 8,283,138
Granted Patent B2
US 8,283,138 · App. 12/542,614 · Granted Oct 9, 2012

Method for the high level expression of active tumor necrosis receptor family member immunoglobulin fusion proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,283,138
App. No.
12/542,614
Granted
Oct 9, 2012
Kind
B2
Abstract

Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification.

Claims (26)

1. A method for increasing expression of active tumor necrosis factor (TNF) receptor family member-Ig Fc fusion proteins and minimizing expression of inactive TNF receptor family member-Ig Fc fusion proteins comprising culturing a mammalian host cell transformed with DNA molecule encoding a desired TNF receptor-Ig fusion protein in a mammalian cell culture having a minimum temperature of about 27° C. to a maximum temperature of less than or equal to 32° C., wherein the transformed host cell is first cultured at a temperature of about 33° C. to about 37° C. for a period of time sufficient to allow growth of said host cell, and wherein the active TNF receptor family member is involved in immune regulation and comprises 2-4 copies of canonical TNF family cysteine-rich domains.

2. The method of claim 1 , wherein the maximum temperature is about 30° C.

3. The method of claim 1 , wherein the maximum temperature is about 32° C.

4. The method of any one of claims 1 - 3 , wherein the TNF receptor family member is a lymphotoxin-β receptor, TNFR-55, TNFR-75, HVEM or a ligand-binding portion thereof.

5. The method of claim 4 , wherein the TNF receptor family member is a lymphotoxin-β receptor or a ligand-binding portion thereof.

6. The method of any one of claims 1 - 3 , further comprising the step of recovering the active TNF receptor family member-Ig Fc fusion proteins from the culture.

7. The method of claim 6 , wherein the active TNF receptor family members are recovered by hydrophobic interaction chromatography.

8. The method of claim 6 , wherein the active TNF receptor family member-Ig Fc fusion proteins are recovered based on their ability to bind an antibody that binds directly to the ligand binding region of the TNF receptor family member and exclusively recognizes the active form of the TNF receptor family member-Ig Fc fusion protein.

9. The method of claim 1 , wherein the mammalian host cell is a CHO cell.

10. The method of claim 1 , wherein the Ig Fc region is human.

11. The method of claim 1 , wherein the Ig Fc region is of an IgG1 isotype.

12. A method for increasing the expression of active TNF receptor family member-Ig Fc fusion proteins and minimizing expression of inactive TNF receptor family member-Ig Fc fusion proteins comprising culturing a mammalian host cell transformed with DNA molecule encoding a desired TNF receptor-Ig fusion protein in a mammalian cell culture having a minimum temperature of about 27° C. to a maximum temperature of less than or equal to 32° C. and recovering the active TNF receptor family member-Ig Fc fusion proteins from the culture, wherein the transformed host cell is first cultured at a temperature of about 33° C. to about 37° C. for a period of time sufficient to allow growth of said host cell, and wherein the active TNF receptor family member is involved in immune regulation and comprises 2-4 copies of canonical TNF family cysteine-rich domains.

13. The method of claim 12 , wherein the maximum temperature is less than or equal to 30° C.

14. The method of claim 12 , wherein the maximum temperature is about 32° C.

15. The method of any one of claims 12 - 14 , wherein the TNF receptor family member is a lymphotoxin-β receptor, TNFR-55, TNFR-75, HVEM or a ligand-binding portion thereof.

16. The method of claim 15 , wherein the TNF receptor family member is a lymphotoxin-B receptor or a ligand-binding portion thereof.

17. The method of claim 12 , wherein the active TNF receptor family member-Ig Fc fusion proteins are recovered by hydrophobic interaction chromatography.

18. The method of claim 12 , wherein the active TNF receptor family member-Ig Fc fusion proteins are recovered based on their ability to bind an antibody that binds directly to the ligand binding region of the TNF receptor family member and exclusively recognizes the active form of the TNF receptor family member-Ig Fc fusion protein.

19. The method of claim 12 , wherein the mammalian host cell is a CHO cell.

20. The method of claim 12 , wherein the Ig Fc region is human.

21. The method of claim 12 , wherein the Ig Fc region is of an IgG1 isotype.

22. The method of claim 1 or 12 , wherein the active TNF receptor family member comprises 3-4 copies of canonical TNF family cysteine-rich domains.

23. The method of claim 1 or 12 , wherein the transformed host cell is first cultured at a temperature of about 37° C. for the period of time sufficient to allow growth of said host cell.

24. A method for increasing expression of active LTβR-Ig Fc fusion proteins and minimizing expression of inactive LTβR-Ig Fc fusion proteins comprising culturing a mammalian host cell transformed with a DNA molecule encoding an LTβR-Ig fusion protein in cell culture having a minimum temperature of about 27° C. and a maximum temperature of less than or equal to 32° C. and isolating the active LTβR-Ig Fc fusion proteins from the culture medium using hydrophobic interaction chromatography, wherein the transformed host cell is first cultured at a temperature of about 33° C. to about 37° C. for a period of time sufficient to allow growth of said host cell.

25. The method of claim 24 , wherein the host cell is a CHO cell.

26. The method of claim 24 or 25 , wherein the transformed host cell is first cultured at a temperature of about 37° C. for the period of time sufficient to allow growth of said host cell.

Assignments (4)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2012
From: BROWNING, JEFFREY; MIATKOWSKI, KONRAD; MEIER, WERNER
To: BIOGEN, INC.
Reel/Frame 028379/0612 →
CHANGE OF NAME Recorded Jun 14, 2012
From: BIOGEN, INC.
To: BIOGEN IDEC MA, INC.
Reel/Frame 028381/0542 →
CHANGE OF NAME Recorded Jun 14, 2012
From: BIOGEN IDEC MA, INC.
To: BIOGEN IDEC MA INC.
Reel/Frame 028381/0633 →